SCHEDULE: Vanguard Group Amends Intellia Therapeutics Stake

The Vanguard Group has filed an amended Schedule 13G for Intellia Therapeutics Inc., reporting 0% beneficial ownership following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 8 to its Schedule 13G for Intellia Therapeutics Inc. Common Stock.
• The filing reports 0% beneficial ownership of Intellia Therapeutics Inc. Common Stock by The Vanguard Group.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Intellia Therapeutics Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting an internal organizational change at Vanguard regarding its reporting structure, rather than a positive or negative statement about Intellia Therapeutics Inc.'s operational or financial performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Intellia Therapeutics Inc.'s future performance or operations.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors. A change in reported ownership by a large entity like Vanguard, particularly to 0% due to an internal realignment, typically reflects a structural or administrative change in how the investment firm manages or reports its holdings rather than a direct change in investment thesis or a divestment based on the underlying company's performance. This is consistent with the explanation provided by Vanguard regarding disaggregated reporting by its subsidiaries.

Stakeholder Impact

• Shareholders of Intellia Therapeutics Inc. may note the administrative change in Vanguard's reported ownership, but it does not imply a change in investment sentiment towards the company from Vanguard's overall managed assets.

Key Dates

Keywords

Intellia Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, SEC filing, investment adviser, common stock